- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01425788
Comparison of Different Up-dosing Schedules With Osiris Phleum Pratense (Osiris)
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Lodz, Poland, 90-153
- Poradnia Alergologii i Chorob Pluc Uniwersyteckiego Szpitala Klinicznego Nr1 im. N. Barlickiego w Lodzi
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Written informed consent obtained before entering the trial
- Male or female >/= 18 years at visit 1
- A clinically relevant history of grass pollen induced allergic rhinoconjunctivitis (moderate to severe) and having received symptomatic treatment during grass pollen season 2010 and 2011
- Positive skin prick test response (wheal diameter >/= 3mm) to Phleum pratense
- Positive specific IgE against Phleum pratense (>/= 0,70KUL / class 2)
- Female subjects of childbearing potential must have a negative pregnancy test and be willing to practice appropriate contraceptive methods until Visit 4
- Subjects willing and able to comply with trial protocol regimen
Exclusion Criteria:
- Subjects included in another protocol (treatment intervention and/or investigational medicine product) or having participated in another clinical trial within 30 days prior to visit 1
- A clinically relevant history of symptomatic seasonal allergic rhinoconjunctivitis caused by an allergen (e.g. hazel, alder, birch, ash) to which the subject will be exposed during the 30-day treatment period.
- A clinically relevant medical history of symptomatic perennial allergy to allergen(s) to which the subject is regularly exposed (e.g. cat, house dust mites).
- Known sensitization (history of positive SPT) to food allergens with oral allergy syndrome
- Uncontrolled asthma (in accordance with GINA guidelines) within the last 12 months
- FEV < 60% of predicted within the last 12 months
- Severe asthma exacerbation(s) within the last 12 months
- A clinically relevant chronic disease (>/= 3 months) (e.g fibrosis, malignancy, type 1 diabetes mellitus, malabsorption or malnutrition, renal or hepatic insufficiency)
- Malignancy or systemic disease affecting the immune system (e.g. autoimmune disease, immune complex disease or immune deficiency disease)
- Inflammatory conditions in the oral cavity with severe symptoms such as oral lichen planus with ulcerations or severe oral mycosis or dental extraction at randomisation
- Medical history of recurrent urticaria or atopic dermatitis during the last 2 years
- Currently receiving treatment preventing the initiation of SIT (e.g. tricyclic antidepressants, mono amine oxidase inhibitors (MAOIs) and catechol-O-methyl transferase inhibitors (COMT inhibitors))
- History of allergy, hypersensitivity, or intolerance to the excipients of the investigational medicinal product
- Being immediate family of the investigator or trial staff, defined as the investigator's / staff's spouse, parent, grandparent, child or grandchild
- History of drug induced (incl. immunotherapy) facial angioedema (including experience of Quincke oedema) or a family (parents or siblings) history of hereditary angioedema
- Anticipated use of any prohibited medication within the specified time windows as defined in the protocol
- Previous treatment by immunotherapy with grass pollen for more than one month within the last 5 years
- Any clinically significant condition or situation, other than the condition being studied, that in the opinion of the investigator would interfere with the trial evaluations or optimal participation
- History of anaphylaxis with cardio respiratory symptoms (e.g. food allergy, drugs or an idiopathic reaction)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Osiris Phleum pratense - Group A
Group A up-dosing schedule from 1IR (index of Reactivity) /day to 240 IR/day in 11 days and thereafter 300 IR/day in 19 days. Day 1-6: 1,2,4,6,8,10 IR/day Day 7-11: 30, 60, 120, 180, 240 IR/day Day 12-30: 300 IR/day |
|
ACTIVE_COMPARATOR: Osiris Phleum pratense - Group B
Group B Up-dosing schedule: Day 1-5: 50 IR/day Day 6-10: 150 IR/day Day 11-30: 300 IR/day |
|
ACTIVE_COMPARATOR: Osiris Phleum pratense - Group C
Group C up-dosing schedule: Day 1-10: 50 IR/day Day 11-20: 150 IR/day Day 21-30: 300 IR/day |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tolerability based on reporting of adverse events
Time Frame: An average of 42 days per subject
|
Recording of adverse events are performed during the entire trial period, from screening to final follow-up contact.
|
An average of 42 days per subject
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Subject satisfaction
Time Frame: Measured at "End of treatment/end of trial Visit"
|
To compare the subjects' satisfaction of the different dosing schedules at end of the trial (after 30 days of treatment with trial medication).
|
Measured at "End of treatment/end of trial Visit"
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Piotr Kuna, Prof.med, Uniwersytecki Szpital Kliniczny Nr1, Lodz, Poland
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- OS-G-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rhino-conjunctivitis
-
AnergisInflamax Research IncorporatedCompletedAllergic Rhino-ConjunctivitisCanada
-
Aalborg UniversityCompletedQuality of Life | Hypersensitivity | Asthma | Effects of Immunotherapy | Rhino-Conjunctivitis
-
Laboratoires TheaCompletedSeasonal Allergic ConjunctivitisFrance
-
Bausch & Lomb IncorporatedCompletedSeasonal Allergic ConjunctivitisSingapore
-
Bausch & Lomb IncorporatedCompletedSeasonal Allergic ConjunctivitisUnited States
-
Eleven BiotherapeuticsCompletedAllergic Conjunctivitis (AC)United States
-
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical...CompletedSeasonal Allergic ConjunctivitisChina
-
Clinical Research Center of FloridaOcular Therapeutix, Inc.CompletedBilateral Conjunctivitis (Disorder)United States
-
NovartisAlcon ResearchCompletedSeasonal Allergic ConjunctivitisChina
-
Ocular Therapeutix, Inc.ORA, Inc.CompletedChronic Allergic Conjunctivitis
Clinical Trials on Osiris Phleum pratense
-
Rigshospitalet, DenmarkTRYG FoundationCompleted
-
Bispebjerg HospitalALK-Abelló A/SCompletedAllergic Rhinitis Due to Grass PollensDenmark
-
ALK-Abelló A/SCompletedAllergic RhinoconjunctivitisSpain
-
Aarhus University HospitalUniversity of Aarhus; ALK-Abelló A/S; Lundbeck FoundationCompleted
-
ALK-Abelló A/SCompleted
-
Laboratorios Leti, S.L.CompletedSeasonal Allergic RhinitisSpain, Hungary
-
ALK-Abelló A/SCompletedGrass Pollen Induced Allergic RhinoconjunctivitisGermany
-
Roxall Medicina España S.ACompletedAllergic RhinoconjunctivitisSpain
-
Aarhus University HospitalUniversity of Aarhus; University Hospital, LinkoepingActive, not recruitingAllergic Rhinitis Due to Grass Pollen | Allergic Asthma | Allergic Conjunctivitis of Both EyesDenmark, Sweden
-
AbbottCompletedSeasonal Allergic RhinitisRussian Federation